20/20 Biolabs, Inc. Common Stock (AIDX)vsJohnson & Johnson (JNJ)
AIDX
20/20 Biolabs, Inc. Common Stock
$0.41
+0.02%
HEALTHCARE · Cap: $6.02M
JNJ
Johnson & Johnson
$267.59
-1.61%
HEALTHCARE · Cap: $648.67B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 4799871% more annual revenue ($97.93B vs $2.04M). JNJ leads profitability with a 21.5% profit margin vs -285.0%. JNJ earns a higher WallStSmart Score of 59/100 (C).
AIDX
Avoid28
out of 100
Grade: F
JNJ
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AIDX.
Margin of Safety
-89.2%
Fair Value
$141.39
Current Price
$267.59
$126.20 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 36.5% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -354.6% — below average capital efficiency
Negative free cash flow — burning cash
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 0.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : AIDX
The strongest argument for AIDX centers on Revenue Growth, Debt/Equity. Revenue growth of 36.5% demonstrates continued momentum.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bear Case : AIDX
The primary concerns for AIDX are EPS Growth, Market Cap, Return on Equity.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
AIDX profiles as a hypergrowth stock while JNJ is a mature play — different risk/reward profiles.
JNJ carries more volatility with a beta of 0.23 — expect wider price swings.
AIDX is growing revenue faster at 36.5% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 28/100), backed by strong 21.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
20/20 Biolabs, Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
20/20 Biolabs, Inc. (AIDX) is a pioneering biotechnology company dedicated to advancing genomic research and diagnostics through its cutting-edge laboratory services. Focused on improving the accuracy and efficiency of genetic testing for both clinical and research applications, the company is set to establish itself as a leader in the molecular diagnostics market. With a strategic emphasis on personalized medicine and a robust portfolio of state-of-the-art technologies, 20/20 Biolabs is well-positioned to meet the surging demand for genomic data and capitalize on emerging opportunities within the dynamic biotechnology landscape. Its innovative approach and strong market presence reflect a promising growth trajectory in an industry characterized by rapid advancements.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?